Skip to main content

Table 1 Mutated cancer genes and available targeted therapeutics

From: Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications

Gene Mutation frequency in this study, n (%) Actionable mutations, n (%) Targeted therapy
EGFRa 231 (25) 202 (22) EGFR TKIs
BRAFa 34 (3.6) 28 (3.0) Vemurafenib, dabrafenib
HER2a 16 (1.7) 16 (1.7) Afatinib, trastuzumab
KRAS, HRAS, NRAS 298 (32) 298 (32) MEK inhibitors
CDKN2A 38 (4.1) 38 (4.1) Cell cycle inhibitors
IDH1, IDH2 6 (0.64) 6 (0.64) IDH inhibitors
PIK3CA, PTEN 55 (5.8) 55 (5.8) PI3 kinase inhibitors
ATM 39 (4.2) 39 (4.2) PARP inhibitors
STK11 26 (2.8) 26 (2.8) mTOR inhibitors
  1. aNCCN guideline genes